Eli Lilly said it has started selling single-dose vials of its uber-popular weight-loss drug Zepbound as demand soars – and the smaller doses cost 50% less than rival drugs.
The more affordable vials are marketed toward patients whose health insurance will not reimburse them for weight-loss medications.
The drugmaker said it will sell 2.5 milligram and 5 milligram vials – now the two lowest doses of Zepbound – for $399 and $549 for a month’s supply on its website, LillyDirect.
Lilly and its Danish rival Novo Nordisk have struggled to keep up with skyrocketing demand.
Zepbound and Novo’s Wegovy have faced shortages for most of this year, according to the US Food and Drug Administration.
Zepbound and Wegovy are currently listed as available, but still in shortage, according to the FDA.
The smaller vials will help boost Lilly’s supply and help the company meet high demand as obesity drugs have become a trend.
